Annexon ANNX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Regeneron PharmaceuticalsREGN

$266.8M+13.8%

Jade BiosciencesJBIO

$808K+159%

Dianthus TherapeuticsDNTH

$1.36M-2.3%

Cullinan Therapeutics, Inc.CGEM

$2.07M+36.3%

Vor BiopharmaVOR

$2.94M-90.5%

Artiva Biotherapeutics, Inc.ARTV

$9.85M-24.9%

FAQ

What is Annexon's operating lease liabilities (total)?

Annexon (ANNX) reported operating lease liabilities (total) of $25.43M in Q1 2026.

How has Annexon's operating lease liabilities (total) changed year-over-year?

Annexon's operating lease liabilities (total) decreased by 10.2% year-over-year, from $28.31M to $25.43M.

What is the long-term trend for Annexon's operating lease liabilities (total)?

Over 4 years (2021 to 2025), Annexon's operating lease liabilities (total) has grown at a -6.7% compound annual growth rate (CAGR), from $34.59M to $26.2M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.